User login
Key clinical point: A higher proportion of patients with episodic migraine (EM), chronic migraine (CM), or treatment-resistant migraine receiving galcanezumab vs placebo achieved a ≥50% response within the first 3 months of treatment, which was sustained for 4-6 months.
Major finding: Galcanezumab vs placebo was associated with higher odds of clinical response in patients with EM (120 mg galcanezumab: odds ratio [OR] 2.7) and CM (120 mg galcanezumab: OR 19.4; all P < .001), with a higher proportion of galcanezumab- vs placebo-treated patients maintaining ≥50% response for 3-6 months of the double-blind treatment period (P < .001).
Study details: This post hoc analysis included 3348 patients with EM (EVOLVE-1 and EVOLVE-2 trials), CM (REGAIN trial), or EM or CM with 2-4 prior treatment failures (CONQUER trial) who received galcanezumab or placebo.
Disclosures: This study was funded by Eli Lilly and Company or one of its subsidiaries, Indianapolis, IN, USA. Three authors declared being employees of Eli Lilly. SJ Tepper declared ties with various sources, including Eli Lilly.
Source: Tepper SJ et al. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine. Headache. 2023 (May 3). doi: 10.1111/head.14494
Key clinical point: A higher proportion of patients with episodic migraine (EM), chronic migraine (CM), or treatment-resistant migraine receiving galcanezumab vs placebo achieved a ≥50% response within the first 3 months of treatment, which was sustained for 4-6 months.
Major finding: Galcanezumab vs placebo was associated with higher odds of clinical response in patients with EM (120 mg galcanezumab: odds ratio [OR] 2.7) and CM (120 mg galcanezumab: OR 19.4; all P < .001), with a higher proportion of galcanezumab- vs placebo-treated patients maintaining ≥50% response for 3-6 months of the double-blind treatment period (P < .001).
Study details: This post hoc analysis included 3348 patients with EM (EVOLVE-1 and EVOLVE-2 trials), CM (REGAIN trial), or EM or CM with 2-4 prior treatment failures (CONQUER trial) who received galcanezumab or placebo.
Disclosures: This study was funded by Eli Lilly and Company or one of its subsidiaries, Indianapolis, IN, USA. Three authors declared being employees of Eli Lilly. SJ Tepper declared ties with various sources, including Eli Lilly.
Source: Tepper SJ et al. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine. Headache. 2023 (May 3). doi: 10.1111/head.14494
Key clinical point: A higher proportion of patients with episodic migraine (EM), chronic migraine (CM), or treatment-resistant migraine receiving galcanezumab vs placebo achieved a ≥50% response within the first 3 months of treatment, which was sustained for 4-6 months.
Major finding: Galcanezumab vs placebo was associated with higher odds of clinical response in patients with EM (120 mg galcanezumab: odds ratio [OR] 2.7) and CM (120 mg galcanezumab: OR 19.4; all P < .001), with a higher proportion of galcanezumab- vs placebo-treated patients maintaining ≥50% response for 3-6 months of the double-blind treatment period (P < .001).
Study details: This post hoc analysis included 3348 patients with EM (EVOLVE-1 and EVOLVE-2 trials), CM (REGAIN trial), or EM or CM with 2-4 prior treatment failures (CONQUER trial) who received galcanezumab or placebo.
Disclosures: This study was funded by Eli Lilly and Company or one of its subsidiaries, Indianapolis, IN, USA. Three authors declared being employees of Eli Lilly. SJ Tepper declared ties with various sources, including Eli Lilly.
Source: Tepper SJ et al. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine. Headache. 2023 (May 3). doi: 10.1111/head.14494